XT
FTH

XTX Topco’s Faeth Therapeutics FTH Stock Holding History

XTX Topco’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,145
Closed -$30.8K – 3053
2024
Q4 		$30.8K Buy
3,145
+2,449
+352% +$24.6K ﹤0.01% 1974
2024
Q3 		$8.33K Sell
696
-6
-0.9% -$73 ﹤0.01% 1943
2024
Q2 		$8.71K Buy
+702
New +$14.6K ﹤0.01% 1703

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

XTX Topco's FTH Position: Q1 2025 in Review

XTX Topco sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 3,145 shares — an estimated $30.8K sold.

XTX Topco first reported a position in FTH in Q2 2024 and held it in 3 quarters. The position peaked at $30.8K in Q4 2024. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

  • XTX Topco reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
  • XTX Topco sold 3,145 Faeth Therapeutics shares in Q1 2025, an estimated $30.8K.
  • XTX Topco first reported a position in Faeth Therapeutics in Q2 2024 and held it in 3 quarters.
  • XTX Topco's Faeth Therapeutics position peaked at $30.8K in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on XTX Topco's 13F filing for Q1 2025, filed 8 May 2025.